1. Coulie, P. G.; Van den Eynde, B. J.; van der Bruggen, P.; Boon, T., Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014, 14 (2), 135-46.
2. Smyth, M. J.; Dunn, G. P.; Schreiber, R. D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90, 1-50.
3. Motz, G. T.; Coukos, G., Deciphering and reversing tumor immune suppression.
Immunity 2013, 39 (1), 61-73.
4. Mauge, L.; Terme, M.; Tartour, E.; Helley, D., Control of the adaptive immune response by tumor vasculature. Front Oncol 2014, 4, 61.
5. Gobert, M.; Treilleux, I.; Bendriss-Vermare, N.; Bachelot, T.; Goddard-Leon, S.; Arfi, V.; Biota, C.; Doffin, A. C.; Durand, I.; Olive, D.; Perez, S.; Pasqual, N.; Faure, C.; Ray-Coquard, I.; Puisieux, A.; Caux, C.; Blay, J. Y.; Menetrier-Caux, C., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69 (5), 2000-9.
6. De Vlaeminck, Y.; González-Rascón, A.; Goyvaerts, C.; Breckpot, K., Cancer-associated myeloid regulatory cells. Frontiers in Immunology 2016, 7.
7. Van Overmeire, E.; Laoui, D.; Keirsse, J.; Van Ginderachter, J. A.; Sarukhan, A., Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol 2014, 5, 127.
8. Marvel, D.; Gabrilovich, D. I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015, 125 (9), 3356-64.
9. Gajewski, T. F., Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006, 12 (7 Pt 2), 2326s-2330s.
10. Aarntzen, E. H.; Schreibelt, G.; Bol, K.; Lesterhuis, W. J.; Croockewit, A. J.; de Wilt, J. H.; van Rossum, M. M.; Blokx, W. A.; Jacobs, J. F.; Duiveman-de Boer, T.; Schuurhuis, D. H.; Mus, R.; Thielemans, K.; de Vries, I. J.; Figdor, C. G.; Punt, C. J.; Adema, G. J., Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012, 18 (19), 5460-70.
11. Van der Jeught, K.; Bialkowski, L.; Daszkiewicz, L.; Broos, K.; Goyvaerts, C.; Renmans, D.; Van Lint, S.; Heirman, C.; Thielemans, K.; Breckpot, K., Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget 2015, 6 (3), 1359-
81; Marabelle, A.; Kohrt, H.; Caux, C.; Levy, R., Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014, 20 (7), 1747-56.
12. Vasaturo, A.; Di Blasio, S.; Peeters, D. G.; de Koning, C. C.; de Vries, J. M.; Figdor, C. G.; Hato, S. V., Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol 2013, 4, 417.
13. Corthay, A., A three-cell model for activation of naive T helper cells. Scand J Immunol 2006, 64 (2), 93-6.
14. Pennock, N. D.; White, J. T.; Cross, E. W.; Cheney, E. E.; Tamburini, B. A.; Kedl, R. M., T cell responses: naive to memory and everything in between. Adv Physiol Educ 2013,
37 (4), 273-83.
15. Wing, K.; Sakaguchi, S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11 (1), 7-13.
16. Marquez-Rodas, I.; Cerezuela, P.; Soria, A.; Berrocal, A.; Riso, A.; Gonzalez-Cao, M.; Martin-Algarra, S., Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ann Transl Med 2015, 3 (18), 267.
17. Capece, D.; Verzella, D.; Fischietti, M.; Zazzeroni, F.; Alesse, E., Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012, 2012,
926321; Krummel, M. F.; Allison, J. P., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996, 183 (6), 2533-40; Walunas, T. L.; Bakker, C. Y.; Bluestone, J. A., CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996, 183 (6), 2541-50.
REFERENCES
18. Quezada, S. A.; Peggs, K. S.; Curran, M. A.; Allison, J. P., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116 (7), 1935-45.
19. Li, N.; Wang, Y.; Forbes, K.; Vignali, K. M.; Heale, B. S.; Saftig, P.; Hartmann, D.; Black, R. A.; Rossi, J. J.; Blobel, C. P.; Dempsey, P. J.; Workman, C. J.; Vignali, D. A., Metalloproteases regulate T-cell proliferation and effector function via LAG-3. Embo j 2007,
26 (2), 494-504.
20. Huang, C. T.; Workman, C. J.; Flies, D.; Pan, X.; Marson, A. L.; Zhou, G.; Hipkiss, E. L.; Ravi, S.; Kowalski, J.; Levitsky, H. I.; Powell, J. D.; Pardoll, D. M.; Drake, C. G.; Vignali, D. A., Role of LAG-3 in regulatory T cells. Immunity 2004, 21 (4), 503-13; Joosten, S. A.; van Meijgaarden, K. E.; Savage, N. D.; de Boer, T.; Triebel, F.; van der Wal, A.; de Heer, E.; Klein, M. R.; Geluk, A.; Ottenhoff, T. H., Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 2007, 104 (19), 8029-34.
21. Liang, B.; Workman, C.; Lee, J.; Chew, C.; Dale, B. M.; Colonna, L.; Flores, M.; Li, N.; Schweighoffer, E.; Greenberg, S.; Tybulewicz, V.; Vignali, D.; Clynes, R., Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008, 180 (9), 5916-26.
22. Macon-Lemaitre, L.; Triebel, F., The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005, 115 (2), 170-8; Sega, E. I.; Leveson-Gower, D. B.; Florek, M.; Schneidawind, D.; Luong, R. H.; Negrin, R. S., Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One 2014, 9 (1), e86551; Hemon, P.; Jean-Louis, F.; Ramgolam, K.; Brignone, C.; Viguier, M.; Bachelez, H.; Triebel, F.; Charron, D.; Aoudjit, F.; Al-Daccak, R.; Michel, L., MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2014, 186 (9), 5173-83.
23. Anderson, A. C., Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012, 24 (2), 213-6.
24. Kleponis, J.; Skelton, R.; Zheng, L., Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015, 12 (3), 201-8; da Silva Correia, J.; McNeeley, P.; Do, M.; Altobell, L.; Chhoa, M.;
Tomlinson, G.; Sheffer, J.; Kehry, M.; Marino, M.; Laken, H; King, D., Identification and Characterization of a Potent Anti-Human TIM-3 Antagonist. In AACR, Orlando, 2014; Blank, C. U., The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 2014, 26 (2), 204-14; Couzin-Frankel, J., Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342 (6165), 1432-3.
25. Topalian, S. L.; Drake, C. G.; Pardoll, D. M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27 (4), 450-61.
26. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363 (8), 711-23.
27. Topalian, S. L.; Hodi, F. S.; Brahmer, J. R.; Gettinger, S. N.; Smith, D. C.; McDermott, D. F.; Powderly, J. D.; Carvajal, R. D.; Sosman, J. A.; Atkins, M. B.; Leming, P. D.; Spigel, D. R.; Antonia, S. J.; Horn, L.; Drake, C. G.; Pardoll, D. M.; Chen, L.; Sharfman, W. H.; Anders, R. A.; Taube, J. M.; McMiller, T. L.; Xu, H.; Korman, A. J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G. D.; Gupta, A.; Wigginton, J. M.; Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366 (26), 2443-54.
28. Tchekmedyian, N.; Gray, J. E.; Creelan, B. C.; Chiappori, A. A.; Beg, A. A.; Soliman, H.; Perez, B. A.; Antonia, S. J., Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park) 2015, 29 (12); Choudhury, N.; Nakamura, Y., The importance of
REFERENCES
immunopharmacogenomics in cancer treatment: Patient Selection and Monitoring for Immune Checkpoint Antibodies. Cancer Sci 2015.
29. Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo j 1992, 11 (11), 3887-95.
30. Kinter, A. L.; Godbout, E. J.; McNally, J. P.; Sereti, I.; Roby, G. A.; O'Shea, M. A.; Fauci, A. S., The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008, 181 (10), 6738-46.
31. Agata, Y.; Kawasaki, A.; Nishimura, H.; Ishida, Y.; Tsubata, T.; Yagita, H.; Honjo, T., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996, 8 (5), 765-72.
32. Freeman, G. J.; Long, A. J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L. J.; Malenkovich, N.; Okazaki, T.; Byrne, M. C.; Horton, H. F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M. R.; Carreno, B. M.; Collins, M.; Wood, C. R.; Honjo, T., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192 (7), 1027-34.
33. Raimondi, G.; Shufesky, W. J.; Tokita, D.; Morelli, A. E.; Thomson, A. W., Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 2006, 176 (5), 2808-16.
34. Dong, Q.; Siminovitch, K. A.; Fialkow, L.; Fukushima, T.; Downey, G. P., Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. J Immunol 1999, 162 (6), 3220-30.
35. Tamura, H.; Dong, H.; Zhu, G.; Sica, G. L.; Flies, D. B.; Tamada, K.; Chen, L., B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001,
97 (6), 1809-16.
36. Tseng, S. Y.; Otsuji, M.; Gorski, K.; Huang, X.; Slansky, J. E.; Pai, S. I.; Shalabi, A.; Shin, T.; Pardoll, D. M.; Tsuchiya, H., B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193 (7), 839-46.
37. Blank, C.; Kuball, J.; Voelkl, S.; Wiendl, H.; Becker, B.; Walter, B.; Majdic, O.; Gajewski, T. F.; Theobald, M.; Andreesen, R.; Mackensen, A., Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119 (2), 317-
27; Blank, C.; Gajewski, T. F.; Mackensen, A., Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005, 54 (4), 307-14.
38. Butte, M. J.; Keir, M. E.; Phamduy, T. B.; Sharpe, A. H.; Freeman, G. J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27 (1), 111-22.
39. Butte, M. J.; Pena-Cruz, V.; Kim, M. J.; Freeman, G. J.; Sharpe, A. H., Interaction of human PD-L1 and B7-1. Mol Immunol 2008, 45 (13), 3567-72.
40. Park, J. J.; Omiya, R.; Matsumura, Y.; Sakoda, Y.; Kuramasu, A.; Augustine, M. M.; Yao, S.; Tsushima, F.; Narazaki, H.; Anand, S.; Liu, Y.; Strome, S. E.; Chen, L.; Tamada, K., B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010, 116 (8), 1291-8.
41. Maenhout, S. K.; Van Lint, S.; Emeagi, P. U.; Thielemans, K.; Aerts, J. L., Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer 2014, 134 (5), 1077-90.
42. J. Pen, J. A., Thérése Liechtenstein, David Escors and Karine Breckpot, Immunology and Microbiology. In Immune Response Activation, May 29 2014.
43. Wang, L.; Pino-Lagos, K.; de Vries, V. C.; Guleria, I.; Sayegh, M. H.; Noelle, R. J., Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 2008, 105 (27), 9331-6.
44. Francisco, L. M.; Salinas, V. H.; Brown, K. E.; Vanguri, V. K.; Freeman, G. J.; Kuchroo, V. K.; Sharpe, A. H., PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206 (13), 3015-29.
REFERENCES
45. Fife, B. T.; Pauken, K. E.; Eagar, T. N.; Obu, T.; Wu, J.; Tang, Q.; Azuma, M.; Krummel, M. F.; Bluestone, J. A., Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009, 10 (11), 1185-92.
46. Karwacz, K.; Arce, F.; Bricogne, C.; Kochan, G.; Escors, D., PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 2012, 1 (1), 86-88.
47. Karwacz, K.; Bricogne, C.; MacDonald, D.; Arce, F.; Bennett, C. L.; Collins, M.; Escors, D., PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med 2011, 3 (10), 581-92.
48. Liechtenstein, T.; Dufait, I.; Bricogne, C.; Lanna, A.; Pen, J.; Breckpot, K.; Escors, D., PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. J Clin Cell Immunol 2012, S12.
49. Pen, J. J.; Keersmaecker, B. D.; Heirman, C.; Corthals, J.; Liechtenstein, T.; Escors, D.; Thielemans, K.; Breckpot, K., Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther 2014.
50. Casey, S. C.; Tong, L.; Li, Y.; Do, R.; Walz, S.; Fitzgerald, K. N.; Gouw, A. M.; Baylot, V.; Gutgemann, I.; Eilers, M.; Felsher, D. W., MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016.
51. Hugo, W.; Zaretsky, J. M.; Sun, L.; Song, C.; Moreno, B. H.; Hu-Lieskovan, S.; Berent-Maoz, B.; Pang, J.; Chmielowski, B.; Cherry, G.; Seja, E.; Lomeli, S.; Kong, X.; Kelley, M. C.; Sosman, J. A.; Johnson, D. B.; Ribas, A.; Lo, R. S., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2016, 165 (1), 35-44.
52. Taube, J. M.; Anders, R. A.; Young, G. D.; Xu, H.; Sharma, R.; McMiller, T. L.; Chen, S.; Klein, A. P.; Pardoll, D. M.; Topalian, S. L.; Chen, L., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4 (127), 127ra37.
53. Azuma, T.; Yao, S.; Zhu, G.; Flies, A. S.; Flies, S. J.; Chen, L., B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008, 111 (7), 3635-43.
54. Hirano, F.; Kaneko, K.; Tamura, H.; Dong, H.; Wang, S.; Ichikawa, M.; Rietz, C.; Flies, D. B.; Lau, J. S.; Zhu, G.; Tamada, K.; Chen, L., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65 (3), 1089-96.
55. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99 (19), 12293-7.
56. Dong, H.; Strome, S. E.; Salomao, D. R.; Tamura, H.; Hirano, F.; Flies, D. B.; Roche, P. C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V. A.; Celis, E.; Chen, L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8
(8), 793-800.
57. Hamanishi, J.; Mandai, M.; Iwasaki, M.; Okazaki, T.; Tanaka, Y.; Yamaguchi, K.; Higuchi, T.; Yagi, H.; Takakura, K.; Minato, N.; Honjo, T.; Fujii, S., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104 (9), 3360-5.
58. Maine, C. J.; Aziz, N. H.; Chatterjee, J.; Hayford, C.; Brewig, N.; Whilding, L.; George, A. J.; Ghaem-Maghami, S., Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 2014, 63 (3), 215-24.
59. Thompson, R. H.; Gillett, M. D.; Cheville, J. C.; Lohse, C. M.; Dong, H.; Webster, W. S.; Chen, L.; Zincke, H.; Blute, M. L.; Leibovich, B. C.; Kwon, E. D., Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005, 104 (10),
2084-91.
60. Nomi, T.; Sho, M.; Akahori, T.; Hamada, K.; Kubo, A.; Kanehiro, H.; Nakamura, S.; Enomoto, K.; Yagita, H.; Azuma, M.; Nakajima, Y., Clinical significance and therapeutic
REFERENCES
potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13 (7), 2151-7.
61. Gao, Q.; Wang, X. Y.; Qiu, S. J.; Yamato, I.; Sho, M.; Nakajima, Y.; Zhou, J.; Li, B. Z.; Shi, Y. H.; Xiao, Y. S.; Xu, Y.; Fan, J., Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15 (3), 971-9.
62. Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattan, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Alshabanah, M.; Bin Amer, S.; Tulbah, A.; Ajarim, D.; Al-Tweigeri, T.; Dermime, S., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006, 8 (3), 190-8.
63. Muenst, S.; Schaerli, A. R.; Gao, F.; Daster, S.; Trella, E.; Droeser, R. A.; Muraro, M. G.; Zajac, P.; Zanetti, R.; Gillanders, W. E.; Weber, W. P.; Soysal, S. D., Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014, 146 (1), 15-24.
64. Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; Joseph, R. W.; Weber, J. S.; Dronca, R.; Gangadhar, T. C.; Patnaik, A.; Zarour, H.; Joshua, A. M.; Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; Boasberg, P.; Tumeh, P. C.; Chmielowski, B.; Ebbinghaus, S. W.; Li, X. N.; Kang, S. P.; Ribas, A., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369 (2), 134-44; Topalian, S. L.; Sznol, M.; McDermott, D. F.; Kluger, H. M.; Carvajal, R. D.; Sharfman, W. H.; Brahmer, J. R.; Lawrence, D. P.; Atkins, M. B.; Powderly, J. D.; Leming, P. D.; Lipson, E. J.; Puzanov, I.; Smith, D. C.; Taube, J. M.; Wigginton, J. M.; Kollia, G. D.; Gupta, A.; Pardoll, D. M.; Sosman, J. A.; Hodi, F. S., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32 (10), 1020-30.
65. Postow, M. A.; Callahan, M. K.; Wolchok, J. D., Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015, 33 (17), 1974-82.
66. Robert, C.; Ribas, A.; Wolchok, J. D.; Hodi, F. S.; Hamid, O.; Kefford, R.; Weber, J. S.; Joshua, A. M.; Hwu, W. J.; Gangadhar, T. C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R. W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M. A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X. N.; Iannone, R.; Ebbinghaus, S. W.; Kang, S. P.; Daud, A., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014,
384 (9948), 1109-17.
67. Berger, R.; Rotem-Yehudar, R.; Slama, G.; Landes, S.; Kneller, A.; Leiba, M.; Koren-Michowitz, M.; Shimoni, A.; Nagler, A., Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14 (10), 3044-51; Armand, P.; Nagler, A.; Weller, E. A.; Devine, S. M.; Avigan, D. E.; Chen, Y. B.; Kaminski, M. S.; Holland, H. K.; Winter, J. N.; Mason, J. R.; Fay, J. W.; Rizzieri, D. A.; Hosing, C. M.; Ball, E. D.; Uberti, J. P.; Lazarus, H. M.; Mapara, M. Y.; Gregory, S. A.; Timmerman, J. M.; Andorsky, D.; Or, R.; Waller, E. K.; Rotem-Yehudar, R.; Gordon, L. I., Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31 (33), 4199-206.
68. Zou, W.; Wolchok, J. D.; Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016, 8 (328), 328rv4.
69. Liu, X.; Gao, J. X.; Wen, J.; Yin, L.; Li, O.; Zuo, T.; Gajewski, T. F.; Fu, Y. X.; Zheng, P.; Liu, Y., B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003, 197 (12), 1721-30; Shin, T.; Kennedy, G.; Gorski, K.; Tsuchiya, H.; Koseki, H.; Azuma, M.; Yagita, H.; Chen, L.; Powell, J.; Pardoll, D.; Housseau, F., Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med 2003, 198 (1), 31-8; Shin, T.; Yoshimura, K.; Crafton, E. B.; Tsuchiya, H.;
REFERENCES
Housseau, F.; Koseki, H.; Schulick, R. D.; Chen, L.; Pardoll, D. M., In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med 2005, 201 (10), 1531-41.
70. Brahmer, J. R.; Tykodi, S. S.; Chow, L. Q.; Hwu, W. J.; Topalian, S. L.; Hwu, P.; Drake, C. G.; Camacho, L. H.; Kauh, J.; Odunsi, K.; Pitot, H. C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T. M.; Alaparthy, S.; Grosso, J. F.; Korman, A. J.; Parker, S. M.; Agrawal, S.; Goldberg, S. M.; Pardoll, D. M.; Gupta, A.; Wigginton, J. M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366 (26), 2455-65.
71. Homet Moreno, B.; Ribas, A., Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015, 112 (9), 1421-7.
72. Herbst, R. S.; Soria, J. C.; Kowanetz, M.; Fine, G. D.; Hamid, O.; Gordon, M. S.; Sosman, J. A.; McDermott, D. F.; Powderly, J. D.; Gettinger, S. N.; Kohrt, H. E.; Horn, L.; Lawrence, D. P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P. S.; Mellman, I.; Chen, D. S.; Hodi, F. S., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515 (7528), 563-7.
73. Weber, J. S.; D'Angelo, S. P.; Minor, D.; Hodi, F. S.; Gutzmer, R.; Neyns, B.; Hoeller, C.; Khushalani, N. I.; Miller, W. H., Jr.; Lao, C. D.; Linette, G. P.; Thomas, L.; Lorigan, P.; Grossmann, K. F.; Hassel, J. C.; Maio, M.; Sznol, M.; Ascierto, P. A.; Mohr, P.; Chmielowski, B.; Bryce, A.; Svane, I. M.; Grob, J. J.; Krackhardt, A. M.; Horak, C.; Lambert, A.; Yang, A. S.; Larkin, J., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16 (4), 375-84.
74. Boyerinas, B.; Jochems, C.; Fantini, M.; Heery, C. R.; Gulley, J. L.; Tsang, K. Y.; Schlom, J., Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015, 3 (10),
1148-57.
75. Ahmadzadeh, M.; Johnson, L. A.; Heemskerk, B.; Wunderlich, J. R.; Dudley, M. E.; White, D. E.; Rosenberg, S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114 (8), 1537-44; Chapon, M.; Randriamampita, C.; Maubec, E.; Badoual, C.; Fouquet, S.; Wang, S. F.; Marinho, E.; Farhi, D.; Garcette, M.; Jacobelli, S.; Rouquette, A.; Carlotti, A.; Girod, A.; Prevost-Blondel, A.; Trautmann, A.; Avril, M. F.; Bercovici, N., Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 2011, 131 (6), 1300-7; French, J. D.; Kotnis, G. R.; Said, S.; Raeburn, C. D.; McIntyre, R. C., Jr.; Klopper, J. P.; Haugen, B. R., Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012, 97 (6), E934-43.
76. Chatterjee, S.; Lesniak, W. G.; Gabrielson, M.; Lisok, A.; Wharram, B.; Sysa-Shah, P.; Azad, B. B.; Pomper, M. G.; Nimmagadda, S., A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 2016.
77. Teng, M. W.; Ngiow, S. F.; Ribas, A.; Smyth, M. J., Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 2015, 75 (11), 2139-45; Hill, J. A.; Feuerer, M.; Tash, K.; Haxhinasto, S.; Perez, J.; Melamed, R.; Mathis, D.; Benoist, C., Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007, 27 (5), 786-800.
78. Heskamp, S.; Hobo, W.; Molkenboer-Kuenen, J. D.; Olive, D.; Oyen, W. J.; Dolstra, H.; Boerman, O. C., Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res 2015, 75 (14), 2928-36.
79. Josefsson, A.; Nedrow, J. R.; Park, S.; Banerjee, S. R.; Rittenbach, A.; Jammes, F.; Tsui, B.; Sgouros, G., Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res 2016, 76
(2), 472-9; Maute, R. L.; Gordon, S. R.; Mayer, A. T.; McCracken, M. N.; Natarajan, A.; Ring, N. G.; Kimura, R.; Tsai, J. M.; Manglik, A.; Kruse, A. C.; Gambhir, S. S.; Weissman, I. L.;
REFERENCES
Ring, A. M., Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A 2015, 112 (47), E6506-14.
80. Natarajan, A.; Mayer, A. T.; Xu, L.; Reeves, R. E.; Gano, J.; Gambhir, S. S., Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjug Chem 2015, 26 (10), 2062-9.
81. Fransen, M. F.; van der Sluis, T. C.; Ossendorp, F.; Arens, R.; Melief, C. J., Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. In Clin Cancer Res, 2013 Aacr.: United States, 2013; Vol. 19, pp 5381-9.
82. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D., Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157 (2), 220-33.
83. Pardoll, D. M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12 (4), 252-64; Andrews, A., Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. Am Health Drug Benefits 2015, 8 (Spec Issue), 9.
84. Chakravarty, R.; Goel, S.; Cai, W., Nanobody: the "magic bullet" for molecular imaging? Theranostics 2014, 4 (4), 386-98.
85. Vaneycken, I.; Devoogdt, N.; Van Gassen, N.; Vincke, C.; Xavier, C.; Wernery, U.; Muyldermans, S.; Lahoutte, T.; Caveliers, V., Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. Faseb j 2011, 25 (7), 2433-46.
86. Pruszynski, M.; Koumarianou, E.; Vaidyanathan, G.; Revets, H.; Devoogdt, N.; Lahoutte, T.; Zalutsky, M. R., Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 2013, 40 (1), 52-9; D'Huyvetter, M.; Aerts, A.; Xavier, C.; Vaneycken, I.; Devoogdt, N.; Gijs, M.; Impens, N.; Baatout, S.; Ponsard, B.; Muyldermans, S.; Caveliers, V.; Lahoutte, T., Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 2012, 7 (2), 254-64.
87. Gainkam, L. O.; Caveliers, V.; Devoogdt, N.; Vanhove, C.; Xavier, C.; Boerman, O.; Muyldermans, S.; Bossuyt, A.; Lahoutte, T., Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011, 6 (2), 85-92.
88. Vaneycken, I.; Govaert, J.; Vincke, C.; Caveliers, V.; Lahoutte, T.; De Baetselier, P.; Raes, G.; Bossuyt, A.; Muyldermans, S.; Devoogdt, N., In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 2010, 51 (7), 1099-106.
89. Movahedi, K.; Schoonooghe, S.; Laoui, D.; Houbracken, I.; Waelput, W.; Breckpot, K.; Bouwens, L.; Lahoutte, T.; De Baetselier, P.; Raes, G.; Devoogdt, N.; Van Ginderachter, J. A., Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012, 72 (16), 4165-77.
90. Breckpot, K.; Dullaers, M.; Bonehill, A.; van Meirvenne, S.; Heirman, C.; de Greef, C.; van der Bruggen, P.; Thielemans, K., Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003, 5 (8), 654-67.
91. Liechtenstein, T.; Perez-Janices, N.; Blanco-Luquin, I.; Goyvaerts, C.; Schwarze, J.; Dufait, I.; Lanna, A.; Ridder, M.; Guerrero-Setas, D.; Breckpot, K.; Escors, D., Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology 2014, 3 (7), e945378.
92. Goyvaerts, C.; De Groeve, K.; Dingemans, J.; Van Lint, S.; Robays, L.; Heirman, C.; Reiser, J.; Zhang, X. Y.; Thielemans, K.; De Baetselier, P.; Raes, G.; Breckpot, K., Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 2012, 19 (12), 1133-40.
93. Rosenberg, S. A.; Yang, J. C.; Sherry, R. M.; Kammula, U. S.; Hughes, M. S.; Phan, G. Q.; Citrin, D. E.; Restifo, N. P.; Robbins, P. F.; Wunderlich, J. R.; Morton, K. E.; Laurencot, C. M.; Steinberg, S. M.; White, D. E.; Dudley, M. E., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17 (13), 4550-7.
REFERENCES
94. Wilgenhof, S.; Van Nuffel, A. M.; Corthals, J.; Heirman, C.; Tuyaerts, S.; Benteyn, D.; De Coninck, A.; Van Riet, I.; Verfaillie, G.; Vandeloo, J.; Bonehill, A.; Thielemans, K.; Neyns, B., Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011, 34 (5), 448-56.
95. Devoogdt, N.; Xavier, C.; Hernot, S.; Vaneycken, I.; D'Huyvetter, M.; De Vos, J.; Massa, S.; De Baetselier, P.; Caveliers, V.; Lahoutte, T., Molecular imaging using Nanobodies: a case study. Methods Mol Biol 2012, 911, 559-67.
96. Tijink, B. M.; Laeremans, T.; Budde, M.; Stigter-van Walsum, M.; Dreier, T.; de Haard, H. J.; Leemans, C. R.; van Dongen, G. A., Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008, 7 (8), 2288-97.
97. Lin, Y. M.; Sung, W. W.; Hsieh, M. J.; Tsai, S. C.; Lai, H. W.; Yang, S. M.; Shen, K. H.; Chen, M. K.; Lee, H.; Yeh, K. T.; Chen, C. J., High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One 2015, 10 (11),
e0142656.
98. Taube, J. M.; Klein, A.; Brahmer, J. R.; Xu, H.; Pan, X.; Kim, J. H.; Chen, L.; Pardoll, D. M.; Topalian, S. L.; Anders, R. A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenviron